FE65 (APBB1) Human shRNA Lentiviral Particle (Locus ID 322)

CAT#: TL306652V

APBB1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Specifications

Product Data

• Locus ID: 322
• Synonyms: FE65; MGC:9072; RIR
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001164, NM_001257319, NM_001257320, NM_001257321, NM_001257322, NM_001257323, NM_001257324, NM_001257325, NM_001257326, NM_145689, NR_047512, NM_001164.1, NM_001164.2, NM_001164.3, NM_001164.4, NM_145689.1, NM_145689.2, NM_001257324.1, NM_001257322.1, NM_001257320.1, NM_001257320.2, NM_001257321.1, NM_001257321.2, NM_001257326.1, NM_001257326.2, NM_001257325.1, NM_001257325.2, NM_001257323.1, NM_001257323.2, NM_001257319.1, NM_001257319.2, BC010854, BM145723, NM_145689.3, NM_001164.5
• UniProt ID: O00213
• Summary: The protein encoded by this gene is a member of the Fe65 protein family. It is an adaptor protein localized in the nucleus. It interacts with the Alzheimer's disease amyloid precursor protein (APP), transcription factor CP2/LSF/LBP1 and the low-density lipoprotein receptor-related protein. APP functions as a cytosolic anchoring site that can prevent the gene product's nuclear translocation. This encoded protein could play an important role in the pathogenesis of Alzheimer's disease. It is thought to regulate transcription. Also it is observed to block cell cycle progression by downregulating thymidylate synthase expression. Multiple alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Mar 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).